Skip to main content

Table 3 Distribution of resistance phenotypesa among inpatient and outpatient MRSAb

From: Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States

  

Inpatient

Outpatient

Category

Resistance phenotype

n

(%)

n

(%)

Susceptible to all other agents

-

418

(4.1)

245

(5.7)

Single-drug resistant

Eryth

1409

(13.7)

1200

(27.8)

 

Cipro

232

(2.2)

92

(2.1)

 

Gent

8

(0.1)

3

(0.1)

 

Clinda

4

(0.0)c

5

(0.1)

Double-drug resistant

Cipro, Eryth

1854

(18.0)

870

(20.2)

 

Eryth, Clinda

114

(1.1)

104

(2.4)

 

Cipro, Clinda

62

(0.6)

23

(0.5)

 

Cipro, Gent

8

(0.1)

12

(0.3)

 

Cipro, SXT

14

(0.1)

2

(0.0)c

 

Eryth, SXT

2

(0.0)c

1

(0.0)c

 

Eryth, Gent

10

(0.1)

1

(0.0)c

 

Gent, SXT

2

(0.0)c

0

(0.0)

Multidrug-resistant

Cipro, Eryth, Clinda

4915

(47.6)

1417

(32.8)

 

Cipro, Eryth, Gent

30

(0.3)

18

(0.4)

 

Cipro, Eryth, SXT

23

(0.2)

7

(0.2)

 

Cipro, Gent, SXT

18

(0.2)

10

(0.2)

 

Eryth, Clinda, Gent

5

(0.0)

5

(0.1)

 

Cipro, Clinda, Gent

6

(0.1)

3

(0.1)

 

Eryth, Clinda, SXT

2

(0.0)c

1

(0.0)c

 

Eryth, Gent, SXT

0

(0.0)

1

(0.0)c

 

Cipro, Clinda, SXT

2

(0.0)c

0

(0.0)

 

Cipro, Eryth, Lin

3

(0.0)c

0

(0.0)

 

Cipro, Eryth, Clinda, Gent

858

(8.3)

214

(5.0)

 

Cipro, Eryth, Clinda, SXT

58

(0.6)

14

(0.3)

 

Cipro, Eryth, Gent, SXT

12

(0.1)

4

(0.1)

 

Eryth, Clinda, Gent, SXT

2

(0.0)c

0

(0.0)

 

Cipro, Clinda, Gent, SXT

2

(0.0)c

0

(0.0)

 

Cipro, Eryth, Clinda, Gent, SXT

247

(2.4)

63

(1.5)

 

Total n

10,320

 

4,315

 
  1. aAnalysis included the following agents: gentamicin (Gent), erythromycin (Eryth), clindamycin (Clinda), trimethoprim-sulfamethoxazole (SXT), ciprofloxacin (Cipro), vancomycin (Vanc), and linezolid (Lin). Multi-drug resistance included resistance to three or more of the agents listed.
  2. bCumulative data 2002 – March 2005
  3. cn < 0.1% of total